Skip to main content
Retour
Watch Compare

LIGAND PHARMACEUTICALS INC

Qualité des données : 100%
Également cotée sous LGNXZ Nasdaq LGNYZ Nasdaq LGNZZ Nasdaq
LGNDZ
Nasdaq Manufacturing Chemicals
0,00 €
▲ 0,00 € (6,67%)
Cap. Boursière: 32 470,0
Prix
0,00 €
Cap. Boursière
32 470,0
Fourchette du Jour
0,00 € — 0,00 €
Fourchette 52 Semaines
0,00 € — 0,00 €
Volume
32 000
Ouverture 0,00 €
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue declined -0,83% annually over 5 years
ROE of 13,99% — decent returns on equity
Net margin of 46,42% shows strong profitability
Generating 48,91 M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 61,23%
Capital efficient — spends only 0,17% of revenue on capex

Croissance

Revenue Growth (5Y)
-0,83%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)60,40%
Earnings (1Y)N/A
FCF Growth (3Y)3,05%

Qualité

Return on Equity
13,99%
Au-dessus de la moyenne du secteur (-53,47%)
ROIC2,76%
Net Margin46,42%
Op. Margin15,29%

Sécurité

Debt / Equity
N/A
Current Ratio24,69
Interest Coverage8,70

Valorisation

PE (TTM)
0,00
Au-dessus de la moyenne du secteur (-1,47)
P/B Ratio0,00
EV/EBITDA-1,86
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E 0,0 -1,5
P/B 0,0 1,6
ROE % 14,0 -53,5
Net Margin % 46,4 -41,5
Rev Growth 5Y % -0,8 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 60,40% Revenue Growth (3Y) 42,88%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 54,48%
Revenue Growth (5Y) -0,83% Earnings Growth (5Y) 21,48%
Profitability
Revenue (TTM) 268,09 M Net Income (TTM) 124,45 M
ROE 13,99% ROA 10,26%
Gross Margin N/A Operating Margin 15,29%
Net Margin 46,42% Free Cash Flow (TTM) 48,91 M
ROIC 2,76% FCF Growth (3Y) 3,05%
Safety
Debt / Equity N/A Current Ratio 24,69
Interest Coverage 8,70 Asset Turnover 0,22
Working Capital 723,38 M Tangible Book Value 615,10 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 0,00 Forward P/E N/A
P/B Ratio 0,00 P/S Ratio 0,00
PEG Ratio 0,00 Forward PEG N/A
EV/EBITDA -1,86 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 150622,11%
Market Cap 32 470,0 Enterprise Value -139,34 M
Per Share
EPS (Diluted TTM) 6,13 Revenue / Share 13,21
FCF / Share 2,41 OCF / Share 2,43
EPS CAGR (1Y) N/A EPS CAGR (5Y) 16,66%
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,17% FCF Conversion 39,30%
SBC-Adj. FCF 1,16 M Growth Momentum 61,23

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 268,09 M 167,13 M 131,31 M 196,25 M 277,13 M
Net Income 124,45 M -4,03 M 52,15 M -33,36 M 57,14 M
EPS (Diluted) 6,13 -0,22 2,94 -1,98 3,31
Gross Profit — — — — —
Operating Income 41,00 M -22,61 M 11,94 M 3,04 M 78,90 M
EBITDA — — — — —
R&D Expenses 81,18 M 21,43 M 24,54 M 36,08 M 69,01 M
SG&A Expenses — — — — —
D&A 33,78 M 35,24 M 36,52 M 51,53 M 51,07 M
Interest Expense 4,72 M 3,04 M 656 000,0 1,80 M 19,63 M
Income Tax 34,51 M 6,55 M 9,84 M 41,23 M -9,84 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,56 B 941,77 M 787,22 M 762,67 M 1,30 B
Total Liabilities 543,43 M 111,34 M 86,30 M 165,18 M 476,43 M
Shareholders' Equity 1,02 B 830,44 M 700,91 M 597,49 M 821,16 M
Total Debt — — — — —
Cash & Equivalents 174,93 M 72,31 M 22,95 M 45,01 M 19,52 M
Current Assets 832,27 M 331,56 M 237,43 M 263,60 M 464,75 M
Current Liabilities 37,45 M 37,11 M 16,78 M 98,81 M 41,67 M